We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+11.62%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.87B
AUM Growth
+$212M
(+13%)
Cap. Flow
+$49.5M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
45.13%
Holding
78
New
31
Increased
13
Reduced
11
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$75M |
| 2 |
AGN
Allergan plc
AGN
|
+$50M |
| 3 |
AGN
Allergan Inc
AGN
|
+$48.9M |
| 4 |
AbbVie
ABBV
|
+$46.5M |
| 5 |
BEAM
BEAM INC COM STK (DE)
BEAM
|
+$46.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$64.6M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$62M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$58.8M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$51.5M |
| 5 |
CFN
CAREFUSION CORPORATION
CFN
|
+$49.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.15% |
| 2 | Financials | 6.73% |
| 3 | Consumer Staples | 6.5% |
| 4 | Materials | 1.82% |
| 5 | Real Estate | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Eli Lilly
LLY
$1.02T
| $6.14M | 0.33% |
+121,929
| New | +$6.38M |
|
|
ACGN
52
DELISTED
Aceragen Inc
ACGN
| $5.69M | 0.31% |
+24,068
| New | +$4.82M |
|
|
ITMN
53
DELISTED
INTERMUNE INC
ITMN
| $4.17M | 0.22% |
271,100
-2,828,900
| -91% | -$39.7M |
|
54
Thermo Fisher Scientific
TMO
$213B
| $3.77M | 0.2% |
+40,926
| New | +$3.7M |
|
55
Mettler-Toledo International
MTD
$28.6B
| $3M | 0.16% |
+12,514
| New | +$2.82M |
|
56
Cooper Companies
COO
$14.1B
| $2.85M | 0.15% |
87,876
+57,476
| +189% | +$1.85M |
|
57
Healthpeak Properties
DOC
$15.1B
| $2.76M | 0.15% |
73,895
+24,924
| +51% | +$972K |
|
58
Celldex Therapeutics
CLDX
$2.99B
| $932K | 0.05% |
1,753
-94,914
| -98% | -$32.5M |
|
|
59
Biogen
BIIB
$30B
| – | – |
-300,000
| Closed | -$64.6M |
|
60
Community Health Systems
CYH
$393M
| – | – |
-786,500
| Closed | -$30.5M |
|
61
HCA Healthcare
HCA
$87.2B
| – | – |
-800,000
| Closed | -$28.8M |
|
62
Humana
HUM
$43.7B
| – | – |
-125,000
| Closed | -$10.5M |
|
63
Incyte
INCY
$24.2B
| – | – |
-775,000
| Closed | -$17.1M |
|
64
Jazz Pharmaceuticals
JAZZ
$15.9B
| – | – |
-250,000
| Closed | -$17.2M |
|
65
Monster Beverage
MNST
$94.3B
| – | – |
-4,500,000
| Closed | -$45.6M |
|
66
Nektar Therapeutics
NKTR
$2.39B
| – | – |
-266,667
| Closed | -$46.2M |
|
|
UHT
67
Universal Health Realty Income Trust
UHT
$603M
| – | – |
-14,200
| Closed | -$612K |
|
|
68
Vertex Pharmaceuticals
VRTX
$121B
| – | – |
-775,000
| Closed | -$62M |
|
69
Welltower
WELL
$169B
| – | – |
-20,700
| Closed | -$1.39M |
|
|
AKRX
70
DELISTED
Akorn Inc
AKRX
| – | – |
-600,000
| Closed | -$8.11M |
|
|
MDCO
71
DELISTED
Medicines Co
MDCO
| – | – |
-1,675,000
| Closed | -$51.5M |
|
|
TMH
72
DELISTED
Team Health Holdings Inc
TMH
| – | – |
-200,000
| Closed | -$8.21M |
|
|
CTRX
73
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| – | – |
-525,000
| Closed | -$25.6M |
|
|
CFN
74
DELISTED
CAREFUSION CORPORATION
CFN
| – | – |
-1,350,000
| Closed | -$49.7M |
|
|
WWAV.B
75
DELISTED
THE WHITEWAVE FOODS COMPANY CLASS B COM STK
WWAV.B
| – | – |
-470,680
| Closed | -$7.15M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2013 Portfolio in Review
As of Q3 2013, HealthCor Management held 78 positions worth $1.87B, up 13% from $1.65B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
HealthCor Management's Q3 2013 filing shows 31 new, 13 increased, 11 reduced and 20 closed positions. Its largest new stake was Zimmer Biomet: 952,750 shares worth $76M. The largest sale was Biogen, an estimated $64.6M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 71% a quarter earlier, followed by Financials and Consumer Staples.
- HealthCor Management's largest Q3 2013 buy was Zimmer Biomet: 952,750 shares worth $76M.
- HealthCor Management added most to Aegerion Pharmaceuticals in Q3 2013, an estimated $25.3M increase.
- HealthCor Management's biggest Q3 2013 reduction was Veradigm Inc. Common Stock, cutting an estimated $58.8M.
- HealthCor Management fully exited Biogen in Q3 2013, selling an estimated $64.6M.
- HealthCor Management's ten largest holdings make up 45% of its $1.87B portfolio in Q3 2013.
- HealthCor Management opened 31 new positions and closed 20 in Q3 2013.
- HealthCor Management's portfolio value rose 13% quarter-over-quarter to $1.87B.
Based on HealthCor Management's 13F filing for Q3 2013, filed 14 Nov 2013.